Jeffrey B. Landau - Jan 18, 2024 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Business Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
Stock symbol
CTMX
Transactions as of
Jan 18, 2024
Transactions value $
$0
Form type
4
Date filed
1/19/2024, 08:40 PM
Previous filing
Dec 22, 2023
Next filing
Mar 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +30K +34.63% $0.00 117K Jan 18, 2024 Direct F1, F2
holding CTMX Common Stock 4.5K Jan 18, 2024 Fidelity Traditional IRA
holding CTMX Common Stock 3.18K Jan 18, 2024 Schwab ROTH IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Award $0 +140K $0.00 140K Jan 18, 2024 Common Stock 140K $1.68 Direct F3
transaction CTMX Performance Stock Units (PSUs) Award $0 +75K $0.00 75K Jan 18, 2024 Common Stock 75K Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date.
F2 Includes 82,205 RSUs.
F3 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F4 Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.